
Jason D Weber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2907274/publications.pdf Version: 2024-02-01



IASON D WERED

#	Article	IF	CITATIONS
1	lt's Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy. Frontiers in Cell and Developmental Biology, 2022, 10, 818744.	3.7	15
2	Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene, 2021, 40, 189-202.	5.9	44
3	Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer. JAMA Oncology, 2021, 7, 1016.	7.1	68
4	8-Azaadenosine and 8-Chloroadenosine are not Selective Inhibitors of ADAR. Cancer Research Communications, 2021, 1, 56-64.	1.7	11
5	Upregulation of 5′-terminal oligopyrimidine mRNA translation upon loss of the ARF tumor suppressor. Scientific Reports, 2020, 10, 22276.	3.3	5
6	Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ. Cancer, 2019, 125, 3225-3233.	4.1	18
7	DHX33 Interacts with AP-2 <i>β</i> To Regulate <i>Bcl-2</i> Gene Expression and Promote Cancer Cell Survival. Molecular and Cellular Biology, 2019, 39, .	2.3	18
8	Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ. Breast Cancer Research, 2019, 21, 120.	5.0	18
9	Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation. ELife, 2019, 8, .	6.0	198
10	The Role of RNA Editing in Cancer Development and Metabolic Disorders. Frontiers in Endocrinology, 2018, 9, 762.	3.5	70
11	Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nature Communications, 2018, 9, 3787.	12.8	112
12	Sabotaging of the oxidative stress response by an oncogenic noncoding RNA. FASEB Journal, 2017, 31, 482-490.	0.5	9
13	DHX33 Transcriptionally Controls Genes Involved in the Cell Cycle. Molecular and Cellular Biology, 2016, 36, 2903-2917.	2.3	24
14	The DHX33 RNA Helicase Promotes mRNA Translation Initiation. Molecular and Cellular Biology, 2015, 35, 2918-2931.	2.3	56
15	Targeting PTEN-defined breast cancers with a one-two punch. Breast Cancer Research, 2015, 17, 51.	5.0	4
16	Elevated DDX21 regulates c-Jun activity and rRNA processing in human breast cancers. Breast Cancer Research, 2014, 16, 449.	5.0	57
17	<i>TP53</i> Mutations and Lung Cancer: Not All Mutations Are Created Equal. Clinical Cancer Research, 2014, 20, 4419-4421.	7.0	25
18	ARF and p53 Coordinate Tumor Suppression of an Oncogenic IFN-β-STAT1-ISG15 Signaling Axis. Cell Reports, 2014, 7, 514-526.	6.4	47

JASON D WEBER

#	Article	IF	CITATIONS
19	ARF tumor suppression in the nucleolus. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 831-839.	3.8	59
20	Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis. Cell, 2013, 153, 1239-1251.	28.9	1,715
21	p19 ^{ARF} and Ras ^{V12} Offer Opposing Regulation of DHX33 Translation To Dictate Tumor Cell Fate. Molecular and Cellular Biology, 2013, 33, 1594-1607.	2.3	25
22	Forget Transcription: Translation Is Where the Action Is. Molecular and Cellular Biology, 2013, 33, 1884-1885.	2.3	5
23	Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models. PLoS ONE, 2013, 8, e77243.	2.5	36
24	Hypergrowth mTORC1 Signals Translationally Activate the ARF Tumor Suppressor Checkpoint. Molecular and Cellular Biology, 2012, 32, 348-364.	2.3	20
25	Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 2012, 486, 353-360.	27.8	922
26	Deconvoluting mTOR biology. Cell Cycle, 2012, 11, 236-248.	2.6	80
27	Knocking down nucleolin expression in gliomas inhibits tumor growth and induces cell cycle arrest. Journal of Neuro-Oncology, 2012, 108, 59-67.	2.9	47
28	Cathepsin K-Cre Causes Unexpected Germline Deletion of Genes in Mice. PLoS ONE, 2012, 7, e42005.	2.5	27
29	RNA Helicase DDX5 Is a p53-Independent Target of ARF That Participates in Ribosome Biogenesis. Cancer Research, 2011, 71, 6708-6717.	0.9	59
30	Identification of DHX33 as a Mediator of rRNA Synthesis and Cell Growth. Molecular and Cellular Biology, 2011, 31, 4676-4691.	2.3	61
31	Loss of <i>Trop2</i> Promotes Carcinogenesis and Features of Epithelial to Mesenchymal Transition in Squamous Cell Carcinoma. Molecular Cancer Research, 2011, 9, 1686-1695.	3.4	55
32	Nucleolar Disruption Ensures Nuclear Accumulation of p21 upon DNA Damage. Traffic, 2010, 11, 743-755.	2.7	29
33	Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice. Cancer Research, 2010, 70, 8937-8947.	0.9	17
34	Synthetic Lethality through Combined Notch–Epidermal Growth Factor Receptor Pathway Inhibition in Basal-Like Breast Cancer. Cancer Research, 2010, 70, 5465-5474.	0.9	64
35	The ARF Tumor Suppressor Regulates Bone Remodeling and Osteosarcoma Development in Mice. PLoS ONE, 2010, 5, e15755.	2.5	20
36	Nucleophosmin Redistribution following Heat Shock: A Role in Heat-Induced Radiosensitization. Cancer Research, 2009, 69, 6454-6462.	0.9	14

JASON D WEBER

#	Article	IF	CITATIONS
37	<i>PIK3CA</i> and <i>PIK3CB</i> Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer. Cancer Research, 2009, 69, 3955-3962.	0.9	198
38	A Non-Tumor Suppressor Role for Basal p19 ^{ARF} in Maintaining Nucleolar Structure and Function. Molecular and Cellular Biology, 2008, 28, 1068-1080.	2.3	40
39	Nucleophosmin Serves as a Rate-Limiting Nuclear Export Chaperone for the Mammalian Ribosome. Molecular and Cellular Biology, 2008, 28, 7050-7065.	2.3	180
40	Nucleophosmin Mediates Mammalian Target of Rapamycin–Dependent Actin Cytoskeleton Dynamics and Proliferation in Neurofibromin-Deficient Astrocytes. Cancer Research, 2007, 67, 4790-4799.	0.9	61
41	Therapeutic Targets in the ARF Tumor Suppressor Pathway. Current Medicinal Chemistry, 2007, 14, 1815-1827.	2.4	40
42	TSC1 Sets the Rate of Ribosome Export and Protein Synthesis through Nucleophosmin Translation. Cancer Research, 2007, 67, 1609-1617.	0.9	36
43	c-Fms Tyrosine 559 Is a Major Mediator of M-CSF-induced Proliferation of Primary Macrophages. Journal of Biological Chemistry, 2007, 282, 18980-18990.	3.4	61
44	Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochemical Journal, 2007, 407, 451-460.	3.7	134
45	A Faster Migrating Variant Masquerades as NICD When Performing in Vitro γ-Secretase Assays with Bacterially Expressed Notch Substratesâ€. Biochemistry, 2006, 45, 5351-5358.	2.5	2
46	Phosphorylation-Dependent Ubiquitination of Cyclin D1 by the SCFFBX4-αB Crystallin Complex. Molecular Cell, 2006, 24, 355-366.	9.7	321
47	Nucleophosmin Is Essential for Ribosomal Protein L5 Nuclear Export. Molecular and Cellular Biology, 2006, 26, 3798-3809.	2.3	191
48	Nucleolar Adaptation in Human Cancer. Cancer Investigation, 2005, 23, 599-608.	1.3	73
49	Cerebrospinal Fluid Proteomic Analysis Reveals Dysregulation of Methionine Aminopeptidase-2 Expression in Human and Mouse Neurofibromatosis 1–Associated Glioma. Cancer Research, 2005, 65, 9843-9850.	0.9	58
50	Proteomic Analysis Reveals Hyperactivation of the Mammalian Target of Rapamycin Pathway in Neurofibromatosis 1–Associated Human and Mouse Brain Tumors. Cancer Research, 2005, 65, 2755-2760.	0.9	283
51	ARF Impedes NPM/B23 Shuttling in an Mdm2-Sensitive Tumor Suppressor Pathway. Molecular and Cellular Biology, 2004, 24, 9327-9338.	2.3	148
52	Defining the molecular basis of Arf and Hdm2 interactions. Journal of Molecular Biology, 2001, 314, 263-277.	4.2	116
53	Solution Structure of the p53 Regulatory Domain of the p19Arf Tumor Suppressor Protein. Biochemistry, 2001, 40, 2379-2386.	2.5	44
54	p53-independent functions of the p19ARF tumor suppressor. Genes and Development, 2000, 14, 2358-2365.	5.9	317

JASON D WEBER

#	Article	IF	CITATIONS
55	Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex. Molecular and Cellular Biology, 2000, 20, 2517-2528.	2.3	260
56	The ARF/p53 pathway. Current Opinion in Genetics and Development, 2000, 10, 94-99.	3.3	612
57	Oncogenic Ras Induces p19ARF and Growth Arrest in Mouse Embryo Fibroblasts Lacking p21Cip1 and p27Kip1 without Activating Cyclin D-dependent Kinases. Journal of Biological Chemistry, 2000, 275, 27473-27480.	3.4	60
58	Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biology, 1999, 1, 20-26.	10.3	854
59	Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes and Development, 1999, 13, 2658-2669.	5.9	734
60	Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proceedings of the United States of America, 1998, 95, 8292-8297.	7.1	820
61	Ablation of Goα Overrides G1Restriction Point Control through Ras/ERK/Cyclin D1-CDK Activities. Journal of Biological Chemistry, 1997, 272, 17320-17326.	3.4	19
62	Ablation of Go α-Subunit Results in a Transformed Phenotype and Constitutively Active Phosphatidylcholine-specific Phospholipase C. Journal of Biological Chemistry, 1997, 272, 17312-17319.	3.4	32
63	Ras-stimulated Extracellular Signal-related Kinase 1 and RhoA Activities Coordinate Platelet-derived Growth Factor-induced G1 Progression through the Independent Regulation of Cyclin D1 and p27KIP1. Journal of Biological Chemistry, 1997, 272, 32966-32971.	3.4	174
64	Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochemical Journal, 1997, 326, 61-68.	3.7	384
65	Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. American Journal of Physiology - Renal Physiology, 1997, 273, G804-G811.	3.4	39